Ravi Pharmascience Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 3 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -30.05%
(FY 2023)
- Profit -53.37%
(FY 2023)
- Ebitda -41.72%
(FY 2023)
- Net Worth 41.99%
(FY 2023)
- Total Assets 15.19%
(FY 2023)
About Ravi Pharmascience
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vinod Singhania and Siddharth Singhania serve as directors at the Company.
- CIN/LLPIN
U24230MH2021PTC353761
- Company No.
353761
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jan 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ravi Pharmascience?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinod Singhania  | Director | 19-Jan-2021 | Current |
| Siddharth Singhania | Director | 19-Jan-2021 | Current |
Financial Performance and Corporate Structure Insights of Ravi Pharmascience.
Ravi Pharmascience Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 30.05% decrease. The company also saw a substantial fall in profitability, with a 53.37% decrease in profit. The company's net worth Soared by an impressive increase of 41.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ravi Pharmascience?
In 2023, Ravi Pharmascience had a promoter holding of 2.00% and a public holding of 98.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Siddharth Colorchem Private LimitedActive 37 years 9 monthsVinod Singhania and Siddharth Singhania are mutual person
Ravi Dyeware Company Private LimitedActive 27 years 8 monthsVinod Singhania and Siddharth Singhania are mutual person
Ravi Biolife Private LimitedActive 3 years 11 monthsVinod Singhania and Siddharth Singhania are mutual person
_PRIVATE_LIMITED.webp)
_PRIVATE_LIMITED.webp)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ravi Pharmascience?
Ravi Pharmascience has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ravi Pharmascience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ravi Pharmascience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
